哮喘用药是否已跟上证据?一项12年人群趋势研究
该研究基于加拿大不列颠哥伦比亚省2002至2013年行政健康数据库,纳入15至67岁符合哮喘病例定义的患者,评估短效β2受体激动剂(SABA)的不适当与过度处方及控制药与缓解药平衡的趋势。结果显示7.3%的患者年存在不适当SABA处方,该比例每年相对下降5.3%;但过度SABA处方随哮喘病程每年增加23.3%、随年龄每年增加5.1%。
要点
- 不适当SABA处方占比7.3%,研究期间每年相对下降5.3%。
- 过度SABA处方随哮喘病程每年增加23.3%,随年龄每年增加5.1%。
- 哮喘病程第1年6.3%患者有不适当SABA使用指标,前3年下降后回升。
核心结论
- 尽管证据充分,不适当SABA处方仍普遍存在。
- 过度SABA使用可能解释老年患者哮喘高死亡率。
- 不适当处方在研究期间下降,但随哮喘病程延长而增加。
研究设计与样本
- 回顾性队列研究,基于加拿大不列颠哥伦比亚省2002至2013年行政健康数据库。
- 纳入15至67岁符合验证性哮喘病例定义的患者。
主要发现
- 7.3%的患者年存在不适当SABA处方,该比例每年相对下降5.3%(P < .001)。
- 哮喘病程第1年6.3%患者有不适当SABA使用指标,前3年内下降但此后增加。
- 过度SABA处方随哮喘病程每年增加23.3%(P < .001),随年龄每年增加5.1%(P < .001)。
临床怎么用
- 呼吸科医生应关注哮喘患者SABA使用情况,识别不适当与过度处方。
- 对病程较长和年龄较大的哮喘患者,需警惕过度SABA使用风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The importance of balance between controller and reliever medications in asthma is recognized. However, to our knowledge, the extent to which real-world practice has caught up with evidence-based guidelines has not been studied. METHODS: This was a retrospective cohort study of individuals 15 to 67 years of age who satisfied a validated case definition of asthma in the administrative health database of British Columbia, Canada between 2002 and 2013. Each patient-year was assessed for inappropriate and excessive prescription of short-acting beta-agonists (SABAs) and the balance between controller and reliever medications. Trends on three time axes were evaluated: calendar time, time course of asthma, and age. Poisson regression was used to test for a linear trend. RESULTS: Three hundred fifty-six thousand, one hundred twelve patients (56.5% female sex; mean age, 30.5 years) contributed 2.6 million patient-years. In 7.3% of the patient-years, SABAs were prescribed inappropriately. This proportion dropped by a relative rate of 5.3% per year (P < .001). In the first year of asthma, 6.3% of patients had indicators of inappropriate SABA use, which dropped within the first 3 years but increased thereafter. Excessive prescription of SABAs increased rapidly during the time course of asthma (change of 23.3% per year; P < .001) and by age (change of 5.1% per year; P < .001). CONCLUSIONS: Despite overwhelming evidence regarding the risks, inappropriate prescription for SABAs was prevalent. Excessive SABA use might explain high asthma mortality in older patients. Inappropriate prescriptions declined over the study period but increased over the time course of asthma. These trends might have contributed to the declining asthma hospitalization rates in British Columbia, but there remain gaps in care and potential for improvement in asthma outcomes.
引用
- Sadatsafavi M, Tavakoli H, Lynd L, et al. Has Asthma Medication Use Caught Up With the Evidence?: A 12-Year Population-Based Study of Trends. Chest. 2016. PMID: 27815152. doi:10.1016/j.chest.2016.10.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。